Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Benjamin Larimer
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
CytoSite BioPharma, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Benjamin M. Larimer is a co-founder of the private start-up company CytoSite BioPharma, Inc. He holds equity in the company and will receive income from the company for consulting services. CytoSite BioPharma, Inc. seeks to predict and monitor response to immuno-oncology therapy, as well other indications in which immune cell activity modulates or directly reflects disease activity, and is developing a platform technology centered on imaging and utilizing granzyme B enzyme activity. The research project involves the use of granzyme B PET imaging to effectively measure response to immunotherapy for the treatment of cancer. The results of this study could therefore be of interest to the company.
Quantitative PET Imaging for Oncologic Immunotherapy Response Prediction
Project Narrative Immune checkpoint inhibitors activate the immune system to recognize and attack cancer cells, and have markedly advanced treatment options for patients with a broad variety of cancers. However, standard imaging methods are often not useful in response assessment of immune modulators due to a lack of change in tumor size or metabolic activity with an immune cell infiltrate. To address this unmet clinical and research need, a novel PET imaging approach will be utilized to measure T cell activation within a tumor as a new imaging paradigm for tumoral response evaluation to immune modulators.
Filed on October 02, 2017.
Tell us what you know about Benjamin Larimer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Benjamin Larimer filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Benjamin M. Larimer | University of Alabama at Birmingham | Conflict of Interest | Cytosite Biopharma Inc. | >$600,000 |
| Benjamin M. Larimer | University of Alabama at Birmingham | Conflict of Interest | Cytosite Biopharma Inc. | $60,000 - $79,999 |
| Benjamin Larimer | Massachusetts General Hospital | Conflict of Interest | CytoSite BioPharma, Inc. | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.